biotech · Amyotrophic Lateral Sclerosis (ALS) · Amyotrophic Lateral Sclerosis · BCLI
BRAINSTORM CELL THERAPEUTICS
BRAINSTORM CELL THERAPEUTICS INC.
BRAINSTORM CELL THERAPEUTICS patent portfolio — 8 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- NEW YORK, NY, USA
- Founded
- 2004
- Employees
- 30
- Programs
- 5
- Drugs
- 5
- Patents
- 8
BRAINSTORM CELL THERAPEUTICS patents
8 pharmaceutical patents indexed for BRAINSTORM CELL THERAPEUTICS. 0 expire within 24 months.
BRAINSTORM CELL THERAPEUTICS has 8 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12233092
MSC-NTF specific exosomes and use thereof
granted -
US 11185572
Mesenchymal stem cells for the treatment of CNS diseases
granted -
US 10564149
Populations of mesenchymal stem cells that secrete neurotrophic factors
granted -
US 10052363
Mesenchymal stem cells for the treatment of CNS diseases
granted -
US 10046010
Methods of generating mesenchymal stem cells which secrete neurotrophic factors
granted -
US 9474787
Mesenchymal stem cells for the treatment of CNS diseases
granted -
US 8900574
Mesenchymal stem cells for the treatment of CNS diseases
granted -
US 8663987
Mesenchymal stem cells for the treatment of CNS diseases
granted
Frequently asked questions
How many patents does BRAINSTORM CELL THERAPEUTICS have?
8 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do BRAINSTORM CELL THERAPEUTICS patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.